{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T00:29:46Z","timestamp":1669422586029},"reference-count":33,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["mol clin onc"],"DOI":"10.3892\/mco.2019.1899","type":"journal-article","created":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T10:41:57Z","timestamp":1563446517000},"source":"Crossref","is-referenced-by-count":2,"title":["Combination chemotherapy with TAS\u2011102 plus bevacizumab in salvage\u2011line treatment of metastatic colorectal cancer: A single\u2011center, retrospective study examining the prognostic value of the modified Glasgow Prognostic Score in salvage\u2011line therapy of metastatic colorectal cancer"],"prefix":"10.3892","author":[{"given":"Nobuhisa","family":"Matsuhashi","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, Gifu University School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Gifu University School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital, Gifu 501\u20111194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonari","family":"Suetsugu","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Gifu University School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Fukada","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Gifu University School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Gifu University School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Tokumaru","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Gifu University School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeharu","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Gifu University School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryutaro","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Gifu University School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Tanahashi","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Gifu University School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Matsui","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Gifu University School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Gifu University School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Gifu University School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Yamaguch","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Gifu University School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Futamura","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Gifu University School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Gifu University School of Medicine, Gifu 501\u20111194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2019,7,18]]},"reference":[{"key":"key20200713202545_b1-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1158\/1055-9965.EPI-09-0090","article-title":"International trends in colorectal cancer incidence rates","volume":"18","author":"Center","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key20200713202545_b2-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.clcc.2014.06.004","article-title":"Adaptation of international guidelines for metastatic colorectal cancer: An Asian consensus","volume":"13","author":"Cheng","year":"2014","journal-title":"Clin Colorectal Cancer"},{"key":"key20200713202545_b3-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancersin 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"key20200713202545_b4-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3109\/02841861003733713","article-title":"Trends in colorectal cancer in the south of the Netherlands 1975\u20132007: rectal cancer survival levels with colon cancer survival","volume":"49","author":"Lemmens","year":"2010","journal-title":"Acta Oncol"},{"key":"key20200713202545_b5-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.ejca.2013.03.026","article-title":"Improving outcomes in colorectal cancer: where do we go from here?","volume":"49","author":"Van Cutsem","year":"2013","journal-title":"Eur J Cancer"},{"key":"key20200713202545_b6-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"key":"key20200713202545_b7-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/annonc\/mdx816","article-title":"S-1 and irinotecan plus bevacizumab vs. mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): A randomized, open-label, phase III, noninferiority trial","volume":"29","author":"Yamada","year":"2018","journal-title":"Ann Oncol"},{"key":"key20200713202545_b8-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"key":"key20200713202545_b9-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"RECOURSE Study Group. Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J"},{"key":"key20200713202545_b10-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1097\/00005392-199903000-00071","article-title":"Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model","volume":"161","author":"Melnyk","year":"1999","journal-title":"J Urol"},{"key":"key20200713202545_b11-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1172\/JCI8829","article-title":"Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity","volume":"105","author":"Klement","year":"2000","journal-title":"J Clin Invest"},{"key":"key20200713202545_b12-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/S1470-2045(17)30425-4","article-title":"TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): An investigator-initiated, open-label, single-arm, multicentre, phase 1\/2 study","volume":"18","author":"Kuboki","year":"2017","journal-title":"Lancet Oncol"},{"key":"key20200713202545_b13-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"e000411","DOI":"10.1136\/esmoopen-2018-000411","article-title":"Rationale and design of the TRUSTY study: A randomised, multicentre, open-label phase II\/III study of trifluridine\/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy","volume":"3","author":"Yoshino","year":"2018","journal-title":"ESMO Open"},{"key":"key20200713202545_b14-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ctrv.2013.11.007","article-title":"Towards a simple objective framework for the investigation and treatment of cancer cachexia: The glasgow prognostic score","volume":"40","author":"Douglas","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"key20200713202545_b15-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000362601","article-title":"The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor in patients with resectable gastric cancer","volume":"87","author":"Takeno","year":"2014","journal-title":"Oncology"},{"key":"key20200713202545_b16-mco-0-0-1899","article-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version5.0 Published Nov 27, 2017"},{"key":"key20200713202545_b17-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"key":"key20200713202545_b18-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"key":"key20200713202545_b19-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","article-title":"Gruppo Oncologico Nord Ovest.Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest","volume":"25","author":"Falcone","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20200713202545_b20-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1200\/JCO.2004.11.037","article-title":"Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment","volume":"22","author":"Grothey","year":"2004","journal-title":"J Clin Oncol"},{"key":"key20200713202545_b21-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"key20200713202545_b22-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicenter, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"key20200713202545_b23-mco-0-0-1899","first-page":"2135","article-title":"Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts","volume":"33","author":"Tsukihara","year":"2015","journal-title":"Oncol Rep"},{"key":"key20200713202545_b24-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/nm0901-987","article-title":"Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy","volume":"7","author":"Jain","year":"2001","journal-title":"Nat Med"},{"key":"key20200713202545_b25-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J Clin Oncol"},{"key":"key20200713202545_b26-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","article-title":"Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20200713202545_b26a-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1186\/s12885-016-2491-y","article-title":"Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: A cohort study","volume":"16","author":"Kasi","year":"2016","journal-title":"BMC Cancer"},{"key":"key20200713202545_b27-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1017\/S0029665108007131","article-title":"An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer","volume":"67","author":"McMillan","year":"2008","journal-title":"Proc Nutr Soc"},{"key":"key20200713202545_b28-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/sj.bjc.6604828","article-title":"The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer","volume":"100","author":"Deans","year":"2009","journal-title":"Br J Cancer"},{"key":"key20200713202545_b29-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1093\/ajcn\/83.4.735","article-title":"Cachexia: Pathophysiology and clinical relevance","volume":"83","author":"Morley","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"key20200713202545_b30-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1097\/SLA.0b013e3181454171","article-title":"Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer","volume":"246","author":"Ishizuka","year":"2007","journal-title":"Ann Surg"},{"key":"key20200713202545_b31-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/sj.bjc.6606087","article-title":"An inflammation- based prognostic score (mGPS) predicts cancer survival independent of tumour site: A glasgow inflammation outcome study","volume":"104","author":"Proctor","year":"2011","journal-title":"Br J Cancer"},{"key":"key20200713202545_b32-mco-0-0-1899","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1111\/cas.12451","article-title":"Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer","volume":"105","author":"Prager","year":"2014","journal-title":"Cancer Sci"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T19:25:51Z","timestamp":1594668351000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2019.1899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,18]]},"references-count":33,"URL":"https:\/\/doi.org\/10.3892\/mco.2019.1899","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,18]]}}}